

がん対策推進総合研究事業中間・事後評価委員名簿

(○ : 委員長)

片渕 秀隆	くまもと森都総合病院 特別顧問
産科婦人科学	
Mutations in the known DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas <u>H. Katabuchi</u> , B. V. Rees, A. R. Lambers, B. M. Ronnett, M. S. Blazes, F. S. Leach, K. R. Cho, L. Hedrick Cancer Research 55:5556–5560, 1995	
Meiosis-specific ZFP541 repressor complex promotes development progression of meiotic prophase towards completion during mouse spermatogenesis Y. Horisawa-Takada, C. Kodera, K. Takemoto, A. Sakashita, K. Horisawa, R. Maeda, S. Usuki, S. Fujimura, N. Tani, K. Matsuura, R. Shimada, T. Akiyama, H. Niwa, M. Tachibana, T. Ohba, <u>H. Katabuchi</u> , S. H. Namekawa, K. Araki, K. Ishiguro Nature Communications 12: 3184, 2021	
Surgical efficacy and quality of wide resection of pelvic peritoneum in patients with epithelial ovarian cancer A. Nishimura, T. Motohara, J. Morinaga, Y. Iwagoi, A. Sagara, M. Yamamoto, M. Yamaguchi, Y. Miyahara, H. Tashiro, <u>H. Katabuchi</u> Surgical Oncology DOI: 10.1016/j.suronc.2023.101946, 2023	

岸田 徹	NPO 法人がんノート 代表理事
がん患者支援/政策	
岸田徹・AYA 世代のがんが恋愛や結婚に及ぼす影響・がんサバイバーシップ研究（がん研究振興財団）・平成 28 年度	
岸田徹・AYA 世代のがん患者のピアサポート—「がんノート」の役割と展望—保健の科学（杏林書院）・ 61 卷・2019 年 08 月	

佐谷 秀行	藤田医科大学がん医療研究センター・センター長
腫瘍生物学	
<研究論文>	
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H and <u>Saya H</u> : CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth. <i>Cancer Cell</i> 19: 387–400, 2011	
<研究論文>	
Marumoto T, Zhang D and <u>Saya H</u> : Aurora A – A guardian of poles. <i>Nat Rev Cancer</i> 5:42–50, 2005	
<研究論文>	
Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K and <u>Saya H</u> : Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. <i>Cell</i> 114: 585–598, 2003	

白井 千香	枚方市保健所・所長
公衆衛生行政	
<論文>	
今後の地域医療体制の再構築に向けて、新型コロナウイルス感染症対応を振り返る。白井千香, 中里栄介, 豊田誠他, 日本環境感染学会誌 Vol. 39 no. 4, 2024 : 83–87.	
<寄稿>	
保健所等行政職員が大学院で学び研究する現状と課題. 白井千香 公衆衛生 Vol. 88 no. 7, 2024:721–727. 医学書院	
<寄稿>	
新型コロナからの教訓-保健所と地方衛生研究所のモニタリング報告 2023年総説 保健所、地方衛生研究所はどう変わったか？ 白井千香 公衆衛生 Vol. 87 no. 12, 2023:1188–1193. 医学書院	

杉山 雄大	国立国際医療研究センター 研究所 糖尿病情報センター・医療政策研究室長／筑波大学医学医療系ヘルスサービスリサーチ分野 教授
ヘルスサービスリサーチ	
Sugiyama T, Furuno T, Ichinose Y, Iwagami M, Ihana-Sugiyama N, Imai K, Kakuwa T, Rikitake R, Ohsugi M, Higashi T, Iso H, Ueki K. Assessment of cancer risk associated with 7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4] triazolo-[4,3-a]pyrazine-contaminated sitagliptin use: A retrospective cohort study. <i>J Diabetes Investig.</i> 2024 Aug 12.	
Watanabe T, Sugiyama T, Imai K, Higashi T. How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan. <i>Cancer Sci.</i> 2022 May;113(5):1771-1778.	
Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study. <i>Int J Cancer.</i> 2017 Jul 1;141(1):102-111.	

○	土岐 祐一郎 消化器外科学	大阪大学大学院医学系研究科消化器外科学・教授
		<p>Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.</p> <p>Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghierioli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators.</p> <p>N Engl J Med. 2022 Feb 3;386(5):449–462.</p>
		<p>Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study.</p> <p>Adachi S, Takiguchi S, Okada K, Yamamoto K, Yamasaki M, Miyata H, Nakajima K, Fujiwara Y, Hosoda H, Kangawa K, Mori M, Doki Y. Gastroenterology. 2010 Apr;138(4):1312–20.</p>
		<p>Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).</p> <p>Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, Tamura S, Kimura Y, Miyata H, Motoori M, Shiraishi O, Makino T, Satoh T, Mori M, Doki Y.</p> <p>Ann Oncol. 2017 Jan 1;28(1):116–120.</p>

西田 博	医療法人城見会 AMS ニューオータニクリニック内 視鏡センター センター長
消化器病学	
	<i>Helicobacter pylori</i> eradication treatment for gastric carcinoma prevention in asymptomatic or dyspeptic adults: systematic review and Bayesian meta-analysis of randomized controlled trials Terasawa T, Hamashima C, Kato K, Miyashiro I, Yoshikawa T, Tataku R, <u>Nishida H</u> BMJ Open 2019; 9: 9 http://dx.doi.org/10.1136/bmjopen-2018-026002
	Assessment of Cancer Screenings and Impact of Computer Simulation <u>Nishida H</u> , Harada A, Matsumoto T, Tani T, Tatsumi Y, Nagai E, Mayumi S International Journal of Gastroenterology Disorders & Therapy 2015; 2:119 http://dx.doi.org/10.15344/2393-8498/2015/119
	Evidence-based clinical practice guideline for management of colorectal polyps Tanaka S, Saito Y, Matsuda T, Igarashi M, Matsumoto T, Iwao Y, Suzuki Y, <u>Nishida H</u> , Watanabe T, Sugai T, Sugihara K, Tsuruta O, Hirata I, Hiwatashi N, Saito H, Watanabe M, Sugano K, Shinosegawa T J Gastroenterol DOI 10.1007/s00535-014-1021-4, Published online 07 January 2015 J Gastroenterol 2015; 50: 252–260

馬場 秀夫	国立大学法人熊本大学大学院生命科学研究部消化器外科学 教授
外科学一般、消化器外科学、腫瘍学	
<p>Imai K, Baba H: Initially unresectable colorectal liver metastases: the best therapeutic regimens. <i>Lancet Oncol.</i> 2023 Jun 14;S1470-2045(23)00271-1. doi: 10.1016/S1470-2045(23)00271-1.</p>	
<p>Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nat Med</i> 24:968-977, 2018</p>	
<p>Baba H, Yamada Y, Takahashi D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K: S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. <i>ESMO Open</i> 2:e000135, 2017</p>	

真部 淳	北海道大学医学部小児科 教授
小児血液腫瘍学	
JCCG ALL-B12: Evaluation of intensified therapy with vincristine/dexamethasone pulses and asparaginase, and augmented high-dose methotrexate for pediatric B-ALL. Kato M, Okamoto Y, Imamura T, Kada A, Saito AM, Iijima-Yamashita Y, Deguchi T, Ohki K, Fukushima T, Anami K, Sanada M, Taki T, Hashii Y, Inukai T, Kiyokawa N, Kosaka Y, Yoshida N, Yuza Y, Yanagimachi M, Watanabe K, Sato A, Imai C, Taga T, Adachi S, Horibe K, <u>Manabe A</u> , Koh K. J J Clin Oncol,	
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy on newly diagnosed T-cell acute lymphoblastic leukemia in children and young adults: a nationwide, multicenter, phase II trial including randomization in the very high-risk group. Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, <u>Manabe A</u> , Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Lancet Haematol 10:e419–e432, 2023	
Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: A retrospective study by the Ponte di Legno Childhood ALL Working Group. Ohki K, Butler E, Kiyokawa N, Hirabayashi S, Bergmann A, Moericke A, Boer J, Cave H, Cazzaniga G, Yeoh A, Sanada M, Imamura T, Inaba H, Mullighan C, Loh M, Norén-Nyström U, Shih LY, Zaliova M, Pui CH, Haas O, Harrison C, Moorman A, <u>Manabe A</u> . Leukemia 37:212–216, 2023	